GENERALIZED LIPODYSTROPHY
Clinical trials for GENERALIZED LIPODYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new GENERALIZED LIPODYSTROPHY trials appear
Sign up with your email to follow new studies for GENERALIZED LIPODYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lifesaving drug made available for rare fat disorder patients
Disease control OngoingThis study gives the drug metreleptin to people with generalized lipodystrophy, a rare condition that causes severe fat loss and leads to high blood fats and diabetes. Participants, aged 6 months and older, have already received metreleptin in past NIH studies but cannot get it i…
Matched conditions: GENERALIZED LIPODYSTROPHY
Phase: PHASE3 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare fat disorder: experimental drug mibavademab under safety review
Disease control OngoingThis study tests the safety of switching from the current drug metreleptin to a new experimental drug called mibavademab in people with generalized lipodystrophy, a rare condition where the body cannot properly store fat. Nine participants who have been stable on metreleptin will…
Matched conditions: GENERALIZED LIPODYSTROPHY
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC